Form 4: Puma Biotechnology Director Sells Shares Under 10b5-1 Plan

Allison Dorval, a director at Puma Biotechnology, sold 11,000 shares of common stock at an average price of $3.3724 on June 13, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On June 13, 2024, Allison Dorval, a director of Puma Biotechnology, sold 11,000 shares of the company's common stock.
• The sale was executed under a pre-arranged 10b5-1 trading plan adopted on March 6, 2024.
• The shares were sold at a weighted average price of $3.3724, with individual transactions ranging from $3.3001 to $3.5401.
• Following the transaction, Dorval still beneficially owns 33,000 shares of Puma Biotechnology.
• The reporting person has undertaken to provide full information regarding the number of shares purchased at each separate price within the stated ranges upon request.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine transaction under a pre-existing trading plan. There is no indication of positive or negative implications for the company.

Industry Context

Sales by insiders are a normal part of corporate governance. The use of a 10b5-1 plan suggests the sale was pre-planned and not based on any specific non-public information.

Comparison to Industry Standards

• Director share sales are common across the biotechnology industry.
• The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.
• Comparable companies such as Seattle Genetics or Biogen often see similar filings from their directors and officers.

Stakeholder Impact

• The sale of shares by a director could have a minor negative impact on shareholder sentiment, but the use of a 10b5-1 plan mitigates this concern.

Key Dates